Cargando…

Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study

BACKGROUND: Currently, few studies have explored the heterogeneity of symptoms and functions in patients with breast cancer. This study aimed to identify the subgroups of symptoms and functions in women receiving chemotherapy for breast cancer and determine whether the subgroups differed in demograp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Tingting, Zhou, Tingting, Yuan, Changrong, Yu, Chunfang, Ni, Feixia, Sheng, Zhiren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381982/
https://www.ncbi.nlm.nih.gov/pubmed/35991024
http://dx.doi.org/10.3389/fpubh.2022.952710
_version_ 1784769198589739008
author Cai, Tingting
Zhou, Tingting
Yuan, Changrong
Yu, Chunfang
Ni, Feixia
Sheng, Zhiren
author_facet Cai, Tingting
Zhou, Tingting
Yuan, Changrong
Yu, Chunfang
Ni, Feixia
Sheng, Zhiren
author_sort Cai, Tingting
collection PubMed
description BACKGROUND: Currently, few studies have explored the heterogeneity of symptoms and functions in patients with breast cancer. This study aimed to identify the subgroups of symptoms and functions in women receiving chemotherapy for breast cancer and determine whether the subgroups differed in demographic and clinical characteristics. METHODS: A cross-sectional multicenter survey involving five hospitals in Zhejiang, Shanghai, Shandong, and Guangxi provinces of Mainland China was implemented between August 2020 to December 2021. Participants completed questionnaires that included the PROMIS-57, PROMIS cognitive function short form, and demographic and clinical characteristics. Latent class analysis was performed, followed by chi-square test and analysis of variance. Subsequently, significant variables were included in multinomial logistic regression. RESULTS: A total of 1,180 patients were investigated, with an average age of 48.9 years. Three classes were identified: low symptom burdens and functions group (26.2%, Class 1), moderate symptom burdens and functions group (16.9%, Class 2), and low symptom burdens and high functions group (56.9%, Class 3). Compared with patients in Class 1 and 3, those in Class 2 consistently showed a higher tendency of having urban employee health insurance (odds ratio = 2.506, P < 0.05) and rural health insurance (odds ratio = 2.207, P < 0.05). Additionally, patients in Class 2 tended to be in their fourth cycle of chemotherapy. However, receiving chemotherapy and surgery increased the likelihood of belonging to Class 1. CONCLUSIONS: A high proportion of patients experienced varying degrees of symptom and function issues, suggesting that attention is warranted for women with breast cancer undergoing chemotherapy. Patients with the urban employee basic medical system, the new rural cooperative medical system and in the early stage of chemotherapy cycles were more likely to have symptom burdens. Middle-aged postmenopausal women reported varying degrees of cognitive issues. Additionally, surgery increased the presence of potential long-term effects in functional levels.
format Online
Article
Text
id pubmed-9381982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93819822022-08-18 Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study Cai, Tingting Zhou, Tingting Yuan, Changrong Yu, Chunfang Ni, Feixia Sheng, Zhiren Front Public Health Public Health BACKGROUND: Currently, few studies have explored the heterogeneity of symptoms and functions in patients with breast cancer. This study aimed to identify the subgroups of symptoms and functions in women receiving chemotherapy for breast cancer and determine whether the subgroups differed in demographic and clinical characteristics. METHODS: A cross-sectional multicenter survey involving five hospitals in Zhejiang, Shanghai, Shandong, and Guangxi provinces of Mainland China was implemented between August 2020 to December 2021. Participants completed questionnaires that included the PROMIS-57, PROMIS cognitive function short form, and demographic and clinical characteristics. Latent class analysis was performed, followed by chi-square test and analysis of variance. Subsequently, significant variables were included in multinomial logistic regression. RESULTS: A total of 1,180 patients were investigated, with an average age of 48.9 years. Three classes were identified: low symptom burdens and functions group (26.2%, Class 1), moderate symptom burdens and functions group (16.9%, Class 2), and low symptom burdens and high functions group (56.9%, Class 3). Compared with patients in Class 1 and 3, those in Class 2 consistently showed a higher tendency of having urban employee health insurance (odds ratio = 2.506, P < 0.05) and rural health insurance (odds ratio = 2.207, P < 0.05). Additionally, patients in Class 2 tended to be in their fourth cycle of chemotherapy. However, receiving chemotherapy and surgery increased the likelihood of belonging to Class 1. CONCLUSIONS: A high proportion of patients experienced varying degrees of symptom and function issues, suggesting that attention is warranted for women with breast cancer undergoing chemotherapy. Patients with the urban employee basic medical system, the new rural cooperative medical system and in the early stage of chemotherapy cycles were more likely to have symptom burdens. Middle-aged postmenopausal women reported varying degrees of cognitive issues. Additionally, surgery increased the presence of potential long-term effects in functional levels. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9381982/ /pubmed/35991024 http://dx.doi.org/10.3389/fpubh.2022.952710 Text en Copyright © 2022 Cai, Zhou, Yuan, Yu, Ni and Sheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Cai, Tingting
Zhou, Tingting
Yuan, Changrong
Yu, Chunfang
Ni, Feixia
Sheng, Zhiren
Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title_full Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title_fullStr Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title_full_unstemmed Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title_short Heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in China: A multicentre, cross-sectional study
title_sort heterogeneity of symptoms and functions among women receiving chemotherapy for breast cancer in china: a multicentre, cross-sectional study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381982/
https://www.ncbi.nlm.nih.gov/pubmed/35991024
http://dx.doi.org/10.3389/fpubh.2022.952710
work_keys_str_mv AT caitingting heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy
AT zhoutingting heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy
AT yuanchangrong heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy
AT yuchunfang heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy
AT nifeixia heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy
AT shengzhiren heterogeneityofsymptomsandfunctionsamongwomenreceivingchemotherapyforbreastcancerinchinaamulticentrecrosssectionalstudy